ONCAlert | Upfront Therapy for mRCC
Videos  >  

A Phase III Trial Evaluating Iomab-B Prior to HCT in Relapsed/Refractory AML

Edward Agura, MD
Published Online:6:55 PM, Thu December 13, 2018

Edward Agura, MD, Texas Oncology - Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, discusses the phase III SIERRA trial, which is an ongoing trial investigating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML). 

The SIERRA trial is the first randomized phase III study comparing a transplant treatment using a radioiodinated antibody to ablate the marrow, compared to conventional chemotherapy, Agura explains. The study is specifically designed for patients who are over age 65 and have recurrent or relapsed AML. What makes this trial unique is that it allows older patients to undergo a transplant that is potentially curative, Agura says.

Agura says he wants fellow hematologists to know that just because a patient is older and appears to have recurrent leukemia, it is not time to throw in the towel,  but instead it is time to refer them to participate in the SIERRA trial.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.